Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 6/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7132129 | 1.00 | KLK7 (0.36) | KLK7KLK5MMP3ADAM17PRSS1 | |
| SCHEMBL10623957 | 0.82 | CA1 (0.36) | GLA | |
| SCHEMBL2132635 | 0.78 | KLK7 (0.33) | KLK7KLK5USP2SMN1; SMN2 | |
| SCHEMBL2132631 | 0.78 | KLK7 (0.33) | KLK7KLK5USP2SMN1; SMN2 | |
| SCHEMBL3321284 | 0.76 | KLK7 (0.36) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL13205498 | 0.76 | KLK7 (0.57) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL27527337 | 0.76 | KLK7 (0.57) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL8021097 | 0.75 | CHRM2 (0.42) | KLK7KLK5MMP3ADAM17USP2 | |
| SCHEMBL7609856 | 0.75 | USP2 (0.35) | KLK7USP2SMN1; SMN2NR1H2 | |
| SCHEMBL5963617 | 0.75 | KLK7 (0.36) | KLK7KLK5MMP3ADAM17USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-20 | — | — | US | disclosed |
| EP-2056817-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | Bayer HealthCare AG (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008025509-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125073-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF CANCERS OF THE CENTRAL NERVOUS SYSTEM | BCOR, BRDT, TPMT | KLK7 4474/4885KLK5 3596/4885MMP3 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.